Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Enalapril
Drug: Clonidine

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 374

Registration Number: NCT02177461

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole
Drug: Placebo

First Posted Date: 2014-06-27

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 150

Registration Number: NCT02177357

Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 0.28 mcg tiotropium solution
Drug: 0.40 mcg tiotropium solution
Drug: 0.02 mcg tiotropium solution
Drug: 0.08 mcg tiotropium solution
Drug: 0.16 mcg tiotropium solution
Drug: 0.04 mcg tiotropium solution
Drug: Placebo solution

First Posted Date: 2014-06-27

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02177305

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Spiriva (tiotropium bromide) inhalation capsules

First Posted Date: 2014-06-27

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3588

Registration Number: NCT02177318

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Yurihonjou, Japan

Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Lacidipine

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT02177331

Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Hydrochlorothiazide

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 489

Registration Number: NCT02177422

MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Valsartan
Drug: Placebo

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 426

Registration Number: NCT02177396

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Ipratropium bromide / Salbutamol
Drug: Placebo Inhalation solution
Drug: Ipratropium bromide
Drug: COMBIVENT Inhalation Aerosol
Drug: Placebo Inhalation Aerosol

First Posted Date: 2014-06-27

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1118

Registration Number: NCT02177253

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

Phase 1

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: BI 207127 NA
Drug: Placebo

First Posted Date: 2014-06-27

Last Posted Date: 2016-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 75

Registration Number: NCT02176525

Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Terminated

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Berodual® Respimat®, low inspiratory flow rate
Drug: Berodual® Respimat®, medium inspiratory flow rate
Drug: Berodual® Respimat®, high inspiratory flow rate
Drug: Berodual® HFA-MDI, low inspiratory flow rate
Drug: Berodual® HFA-MDI, medium inspiratory flow rate
Drug: Berodual® HFA-MDI, high inspiratory flow rate

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3

Registration Number: NCT02176200

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy